Alcobra Ltd. (NASDAQ:ADHD)’s share price traded down 6.6% during trading on Monday . The stock traded as low as $4.40 and last traded at $4.50, with a volume of 109,532 shares trading hands. The stock had previously closed at $4.82.
Several equities analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on Alcobra in a research report on Tuesday, June 7th. They issued a “buy” rating and a $16.00 target price on the stock. Roth Capital reaffirmed a “buy” rating and issued a $12.00 target price on shares of Alcobra in a research report on Tuesday, June 21st. Zacks Investment Research raised Alcobra from a “sell” rating to a “hold” rating in a research report on Tuesday, July 26th. Jefferies Group reaffirmed a “buy” rating on shares of Alcobra in a research report on Thursday, August 25th. Finally, Goldman Sachs Group Inc. reaffirmed a “buy” rating on shares of Alcobra in a research report on Thursday, September 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $10.09.
The firm has a 50 day moving average of $4.78 and a 200-day moving average of $4.54. The firm’s market capitalization is $130.64 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/12/alcobra-ltd-adhd-stock-price-down-6-6.html
Alcobra (NASDAQ:ADHD) last posted its earnings results on Tuesday, August 30th. The company reported ($0.21) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. On average, equities analysts anticipate that Alcobra Ltd. will post ($0.96) EPS for the current fiscal year.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Alcobra Ltd. and related companies with MarketBeat.com’s FREE daily email newsletter.